Dr. Argeris ("Jerry") Karabelas is a Partner at Care Capital, a life sciences venture capital firm with $500 million under management. Jerry currently serves as Chairman of the Board for several of Care Capital's portfolio companies, including Vanda Pharmaceuticals, NitroMed Pharmaceuticals, Cyreniac Pharmaceuticals and Inotek Pharmaceuticals, and he also serves as a Director for Minster Pharmaceuticals. In addition to these board positions, Jerry also serves as Chairman of Human Genome Sciences and as a Non-Executive Director for SkyePharma. He had previously served on the board of several other companies, including Renovo, Anadys Pharmaceuticals, Acura Pharmaceuticals, and the Fox Chase Cancer Center.
Prior to Care Capital, Jerry was the Founder and Chairman of the Novartis BioVenture Fund. In this role he invested approximately $40 million in 14 portfolio companies. From 1998 to 2000, Jerry was Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG. He had full responsibility for Novartis Pharma, Ciba Vision and Generics representing $12 billion in annual sales. Included in these responsibilities was strategic and operational leadership of R&D with a budget in excess of $2 billion. Prior to joining Novartis, Jerry was Executive Vice President of SmithKline Beecham responsible for US operations, European operations, Regulatory, and Strategic Marketing. He has been responsible for numerous pharmaceutical product approvals and new products launches, including the launch of four $1 billion products.
Jerry holds a Ph.D. in Pharmacokinetics from the Massachusetts College of Pharmacy. He is a member of the Visiting Committee for Health Sciences and Technology at MIT.